1. Home
  2. CRSP vs CVCO Comparison

CRSP vs CVCO Comparison

Compare CRSP & CVCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • CVCO
  • Stock Information
  • Founded
  • CRSP 2013
  • CVCO 1965
  • Country
  • CRSP Switzerland
  • CVCO United States
  • Employees
  • CRSP N/A
  • CVCO N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • CVCO Homebuilding
  • Sector
  • CRSP Health Care
  • CVCO Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • CVCO Nasdaq
  • Market Cap
  • CRSP 4.3B
  • CVCO 4.2B
  • IPO Year
  • CRSP 2016
  • CVCO N/A
  • Fundamental
  • Price
  • CRSP $43.65
  • CVCO $477.04
  • Analyst Decision
  • CRSP Buy
  • CVCO Buy
  • Analyst Count
  • CRSP 18
  • CVCO 2
  • Target Price
  • CRSP $76.60
  • CVCO $487.50
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • CVCO 56.3K
  • Earning Date
  • CRSP 11-05-2024
  • CVCO 01-30-2025
  • Dividend Yield
  • CRSP N/A
  • CVCO N/A
  • EPS Growth
  • CRSP N/A
  • CVCO N/A
  • EPS
  • CRSP N/A
  • CVCO 17.66
  • Revenue
  • CRSP $202,829,000.00
  • CVCO $1,851,947,000.00
  • Revenue This Year
  • CRSP N/A
  • CVCO $10.04
  • Revenue Next Year
  • CRSP $758.18
  • CVCO $7.24
  • P/E Ratio
  • CRSP N/A
  • CVCO $26.80
  • Revenue Growth
  • CRSP 19.31
  • CVCO N/A
  • 52 Week Low
  • CRSP $42.86
  • CVCO $304.10
  • 52 Week High
  • CRSP $91.10
  • CVCO $544.08
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 39.11
  • CVCO 42.58
  • Support Level
  • CRSP $43.40
  • CVCO $489.00
  • Resistance Level
  • CRSP $53.97
  • CVCO $506.99
  • Average True Range (ATR)
  • CRSP 2.37
  • CVCO 9.98
  • MACD
  • CRSP -0.78
  • CVCO -6.25
  • Stochastic Oscillator
  • CRSP 9.53
  • CVCO 0.00

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About CVCO Cavco Industries Inc. When Issued

Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.

Share on Social Networks: